drugset / Trial / NCT06558708

A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

NCT06558708

Phase 2 Recruiting 60 enrolled Gan and Lee Pharmaceuticals, USA
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in China. The aim of the trial is to compare the efficacy, tolerability, and safety of GZR101 Injection and GZR33-70 Injection in type 2 diabetes inadequately controlled on basal/ premixed insulin once daily at least with or without pre-dinner meal-time insulin.

Timeline

Start
2024-06-28
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GZR101 Unknown Subcutaneous
Subject GZR33 Unknown Subcutaneous
Background insulin aspart Protein / enzyme biologic Subcutaneous